- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.11. | Eterna Therapeutics Authorized $1 Mln Share Buyback; Stock Up In Pre-market | 1 | RTTNews | ||
| 25.11. | Eterna Therapeutics initiates $1 million stock buyback | 1 | Investing.com | ||
| 25.11. | Eterna Therapeutics announces up to $1 million stock repurchase program | 2 | Seeking Alpha | ||
| 25.11. | Eterna Therapeutics kündigt Aktienrückkauf im Wert von 1 Million US-Dollar an | 10 | Investing.com Deutsch | ||
| 14.11. | Eterna Therapeutics regains Nasdaq compliance, focuses on cancer therapy | 5 | Investing.com | ||
| 14.11. | Eterna Therapeutics erfüllt wieder Nasdaq-Anforderungen und konzentriert sich auf Krebstherapie | 1 | Investing.com Deutsch | ||
| 14.11. | Eterna Therapeutics regains Nasdaq compliance | 1 | Seeking Alpha | ||
| 14.11. | Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing | 61 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") announced today that it has regained compliance with Nasdaq for continued listing... ► Artikel lesen | |
| ETERNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.11. | Eterna Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Eterna Therapeutics Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 05.11. | Eterna Therapeutics-Aktionär Charles Cherington verkauft Aktien im Wert von 6,54 Millionen US-Dollar | - | Investing.com Deutsch | ||
| 30.10. | Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success | 104 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") today announced the successful completion of a comprehensive financial restructuring... ► Artikel lesen | |
| 29.10. | Eterna Therapeutics announces share issuance and executive agreements | 1 | Investing.com | ||
| 29.10. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10. | Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases | 139 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") and Factor Bioscience Limited ("Factor") today announced an exclusive license... ► Artikel lesen | |
| 27.09. | Eterna Therapeutics inks new license agreement, ends previous Factor Bioscience deals | 1 | Investing.com | ||
| 23.09. | Eterna Therapeutics droht Delisting von der Nasdaq aufgrund von Eigenkapitalmangel | 1 | Investing.com Deutsch | ||
| 23.09. | Eterna Therapeutics faces Nasdaq delisting over equity shortfall | 1 | Investing.com | ||
| 23.09. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | Eterna Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,428 | +29,70 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 10,240 | 0,00 % | Ginkgo Bioworks (NYSE:DNA) Shares Gap Down - Here's Why | ||
| RECURSION PHARMACEUTICALS | 7,660 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,700 | -0,38 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 1,000 | 0,00 % | Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | ||
| ARCTURUS THERAPEUTICS | 16,930 | +2,42 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,900 | 0,00 % | Assertio Holdings, Inc.: Assertio Announces Results of Rolvedon (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study | LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,890 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 6,060 | 0,00 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,420 | +0,54 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,780 | 0,00 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,305 | +9,27 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,270 | +1,42 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| BIO-PATH | 1,330 | 0,00 % | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
Das Unternehmen ETERNA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,285 Euro und damit +14,34 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ETERNA THERAPEUTICS INC finden Sie auf Wallstreet Online.
